Scanning the horizon for high value-add manufacturing science: Accelerating manufacturing readiness for the next generation of disruptive, high-value curative cell therapeutics

Since the Regenerative Medicine sector entered the second phase of its development (RegenMed 2.0) more than a decade ago, there is increasing recognition that current technology innovation trajectories will drive the next translational phase towards the production of disruptive, high value curative...

Full description

Saved in:
Bibliographic Details
Main Authors: Paul C. Hourd, David Williams
Format: Article
Language:English
Subjects:
Disruptive
Gene-editing
Induced pluripotent stem cells
Manufacturing readiness
Manufacturing science
Mechanical engineering not elsewhere classified
Regenerative medicine
Technology readiness
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since the Regenerative Medicine sector entered the second phase of its development (RegenMed 2.0) more than a decade ago, there is increasing recognition that current technology innovation trajectories will drive the next translational phase towards the production of disruptive, high value curative cell and gene based regenerative medicines. In this short report, a long lens look within the pluripotent stem cell therapeutic space, both embryonic and induced, is used to gain early insights on where critical technology and manufacturing challenges may emerge. The report offers a future perspective on the development and innovation that will be needed within manufacturing science to add value in the production and commercialisation of the next generation of advanced cell therapies and precision medicines.